Actively Recruiting

Phase Not Applicable
Age: 45Years - 75Years
MALE
NCT06262633

A Multi-centre Trial on Targeted Microwave Ablation (TMA) for Localized Prostate Cancer

Led by Chinese University of Hong Kong · Updated on 2025-05-06

103

Participants Needed

1

Research Sites

119 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This study is to investigate the efficacy of Targeted Microwave Ablation (TMA) under MRI-Ultrasound fusion and organ-based tracking (OBT) navigation in localized prostate cancer (PCa) in a multi-centre trial.

CONDITIONS

Official Title

A Multi-centre Trial on Targeted Microwave Ablation (TMA) for Localized Prostate Cancer

Who Can Participate

Age: 45Years - 75Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Men aged between 45 and 75 years
  • Life expectancy greater than 10 years at recruitment
  • Able to understand the trial and provide informed, written consent before enrollment and exams
  • Localized low or intermediate risk prostate cancer diagnosed by MRI-Ultrasound fusion targeted biopsy
  • Organ-confined prostate cancer confirmed by MRI
  • PSA level less than 20 ng/mL
  • Presence of 1 or 2 MRI-visible lesions each 15 mm or smaller, with targeted biopsy showing either ISUP grade group 2 or 3, or ISUP grade group 1 with tumor size 10 mm or larger
Not Eligible

You will not qualify if you...

  • Not fit for general or spinal anesthesia
  • Unable to undergo MRI or MR gadolinium contrast (e.g., eGFR less than 50 ml/min)
  • Uncorrectable coagulopathy
  • On anticoagulants or antiplatelets that cannot be stopped (low dose aspirin 80-100 mg is allowed)
  • Prior treatment for prostate cancer
  • Previous pelvic radiotherapy for prostate or other cancer
  • Target lesion larger than 15 mm
  • Lesion located within 10 mm of rectum or sphincter on MRI
  • More than 2 areas of prostate cancer (visible or invisible on MRI)
  • Gleason score 4+4 or any Gleason pattern 5 cancer
  • Systematic biopsy cores showing Gleason 4 pattern cancer not adjacent to target lesions (one core of pure Gleason 3 in contralateral lobe allowed)
  • Definite cT3 or higher disease on imaging (capsular contact without extra-capsular extension allowed)
  • Bladder diseases including stones or cancer
  • Known urethral stricture
  • Suspected or active COVID-19 or SARS-CoV-2 infection

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Peter Ka-Fung CHIU

Shatin, Hong Kong

Actively Recruiting

Loading map...

Research Team

P

Peter Ka-Fung CHIU, PhD,MBChB

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here